• Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 334.78 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.92
▼ -0.0013 (-0.14%)

This chart shows the closing price for BIOC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biocept Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOC

Analyst Price Target is $4.00
▲ +334.78% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Biocept in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 334.78% upside from the last price of $0.92.

This chart shows the closing price for BIOC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Biocept. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/20/2022Maxim GroupSet Target$4.00Low
5/26/2022Maxim GroupLower Target$5.00Low
10/9/2021Brookline Capital AcquisitionReiterated RatingBuyMedium
10/8/2021Brookline Capital ManagementReiterated RatingBuyMedium
12/11/2020Maxim GroupInitiated CoverageBuy$20.00Low
11/13/2020Maxim GroupReiterated RatingBuyLow
8/13/2020Maxim GroupBoost TargetBuy$10.00 ➝ $20.00Medium
8/4/2020Maxim GroupReiterated RatingBuy$10.00Medium
6/23/2020Maxim GroupReiterated RatingBuy$10.00Low
6/1/2020Maxim GroupInitiated CoverageBuy$10.00Medium
5/15/2020Maxim GroupInitiated CoverageBuy$10.00Low
5/14/2020Brookline Capital ManagementInitiated CoverageBuyHigh
4/14/2020Maxim GroupReiterated RatingBuy$10.00Medium
3/6/2020Maxim GroupReiterated RatingBuy$10.00Low
1/8/2020Maxim GroupReiterated RatingBuy$10.00High
5/9/2019Maxim GroupReiterated RatingBuy$30.00High
3/26/2019Maxim GroupInitiated CoverageBuyHigh
10/3/2018Dawson JamesReiterated RatingBuyHigh
5/23/2018Westpark CapitalDowngradeOutperform ➝ HoldLow
4/4/2018Westpark CapitalReiterated RatingOutperform$10.00Medium
11/14/2017Chardan CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $15.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

-0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/5/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Biocept logo
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.92
Low: $0.88
High: $0.94

50 Day Range

MA: $0.98
Low: $0.75
High: $1.20

52 Week Range

Now: $0.92
Low: $0.72
High: $4.40

Volume

913 shs

Average Volume

111,334 shs

Market Capitalization

$15.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Biocept?

The following Wall Street analysts have issued research reports on Biocept in the last year: Brookline Capital Acquisition Corp., Brookline Capital Management, Maxim Group, StockNews.com, and TheStreet.
View the latest analyst ratings for BIOC.

What is the current price target for Biocept?

1 Wall Street analysts have set twelve-month price targets for Biocept in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 334.8%. Maxim Group has the highest price target set, predicting BIOC will reach $4.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Biocept in the next year.
View the latest price targets for BIOC.

What is the current consensus analyst rating for Biocept?

Biocept currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIOC will outperform the market and that investors should add to their positions of Biocept.
View the latest ratings for BIOC.

What other companies compete with Biocept?

How do I contact Biocept's investor relations team?

Biocept's physical mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company's listed phone number is (858) 320-8200 and its investor relations email address is [email protected] The official website for Biocept is www.biocept.com. Learn More about contacing Biocept investor relations.